Specific gut microbial profiles and greater microbial diversity have been correlated with enhanced responses to PD-1, PD-L1, and CTLA-4 blockade therapies in various cancers, possibly due to microbiota-immune modulation or microbiota-drug interaction (15–18). This evidence concerns the gene CD274 and cancer.